Ziming Li
Shanghai Chest Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ziming Li as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:29 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07846358 · This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.Genfleet Therapeutics (Shanghai) Inc. · not yet recruiting · RAS Mutation, Non-small Cell Lung Cancer (NSCLC) · principal investigator
- N/ANCT06930807 · Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung CancerPeking University People's Hospital · recruiting · Non-small Cell Lung Cancer, Minimal Residual Disease, Adaptive Treatment · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:29 UTC. The ranking covers the 200 most relevant of 41 PubMed records, and a shared surname and initials can bring in a namesake. All 41 on PubMed
- Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).J Clin Oncol · 2017335 citationsRCR 9.4
- Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients.Cancer Immunol Immunother · 2020128 citationsRCR 5.2
- 118 citationsRCR 2.5
- D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results.J Thorac Oncol · 202384 citationsRCR 6.1
- 54 citationsRCR 9.6
- 47 citationsRCR 7.3
- Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial.Lancet Respir Med · 202446 citationsRCR 4.7
- A Phase 2 Trial of Concurrent Chemotherapy and Proton Therapy for Stage III Non-Small Cell Lung Cancer: Results and Reflections Following Early Closure of a Single-Institution Study.Int J Radiat Oncol Biol Phys · 201643 citationsRCR 1.7
- Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC.BMC Cancer · 201738 citationsRCR 1.1
- SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study.Signal Transduct Target Ther · 202435 citationsRCR 2.8